FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362561513> ?p ?o ?g. }

• W4362561513 abstract "Cutaneous angiosarcoma (CAS) is a highly malignant tumor with few effective treatments. Although the indication for immune checkpoint inhibitors such as anti-PD-1 antibodies is expected to expand, there are many unknowns regarding the tumor immune microenvironment in CAS, which is generally considered an immunologically “cold” tumor. Our previous study demonstrated that tertiary lymphoid structures (TLSs) were associated with a favorable prognosis in CAS. However, we still don’t know what the difference is between cases of TLS-rich and TLS-poor. Furthermore, the number of TLSs can vary significantly between lesions in the same case, for example, between primary and recurrence. To analyze the changes in the tumor immune microenvironment in CAS in more detail, we performed comprehensive RNA sequencing using a Next-generation sequencer (NGS). Sixty-two samples from 31 cases of CAS treated at Nagoya City University were collected. NGS and gene set enrichment analysis (GSEA) were performed on 15 samples among them. Immunohistochemistry and prognostic analysis by Kaplan-Meier method were performed on all 62 samples. NGS results showed that NY-ESO-1 (CTAG1B) was significantly upregulated in the TLS-positive cases. Immune checkpoint molecules including programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) were upregulated in TLS-negative or TLS-low cases and seemed to associate with the suppression of TLS formation. In a comparison of primary and recurrent lesions, other cancer-testis antigens (CTAs) including XAGE-1B were significantly upregulated in recurrent lesions. The number of infiltrating CD8-positive cells and TLSs showed no significant trend between primary and recurrent lesions. However, the PD-L1 expression of tumor cells was significantly lower in recurrent than in primary lesions. Chemokines correlated with NY-ESO-1 expression were CCL21 and CXCL8, and only CCL21 correlated with the number of TLS. There was no chemokine associated with XAGE-1. NY-ESO-1 and XAGE-1 are detectable by immunohistochemistry. Although each cannot be a prognostic marker by itself, they can be a helpful marker in combination with the number of TLSs. CTAs play an essential role in forming the tumor immune microenvironment in CAS. These findings are evidence that CAS is an immunologically “hot” tumor and provides us with potential therapeutic targets and encourages the expansion of immunotherapy indications." @default.
• W4362561513 created "2023-04-06" @default.
• W4362561513 creator A5030939408 @default.
• W4362561513 creator A5052637717 @default.
• W4362561513 creator A5074473725 @default.
• W4362561513 creator A5075358038 @default.
• W4362561513 creator A5081067710 @default.
• W4362561513 creator A5082909666 @default.
• W4362561513 creator A5087899687 @default.
• W4362561513 date "2023-04-04" @default.
• W4362561513 modified "2023-10-01" @default.
• W4362561513 title "Tumor immune microenvironment of cutaneous angiosarcoma with cancer testis antigens and the formation of tertiary lymphoid structures" @default.
• W4362561513 cites W1499538703 @default.
• W4362561513 cites W1950204667 @default.
• W4362561513 cites W1985594917 @default.
• W4362561513 cites W1986889426 @default.
• W4362561513 cites W2008486456 @default.
• W4362561513 cites W2010457001 @default.
• W4362561513 cites W2021641722 @default.
• W4362561513 cites W2037444287 @default.
• W4362561513 cites W2046645583 @default.
• W4362561513 cites W2086856480 @default.
• W4362561513 cites W2088660904 @default.
• W4362561513 cites W2130410032 @default.
• W4362561513 cites W2137088550 @default.
• W4362561513 cites W2159173286 @default.
• W4362561513 cites W2342335701 @default.
• W4362561513 cites W2402246319 @default.
• W4362561513 cites W2473002818 @default.
• W4362561513 cites W2574631266 @default.
• W4362561513 cites W2588457489 @default.
• W4362561513 cites W2738639820 @default.
• W4362561513 cites W2800346238 @default.
• W4362561513 cites W2801633996 @default.
• W4362561513 cites W2891701762 @default.
• W4362561513 cites W2900972652 @default.
• W4362561513 cites W2943233109 @default.
• W4362561513 cites W2949273159 @default.
• W4362561513 cites W2967881599 @default.
• W4362561513 cites W2969705364 @default.
• W4362561513 cites W2981664880 @default.
• W4362561513 cites W2998795792 @default.
• W4362561513 cites W3000282923 @default.
• W4362561513 cites W3000311037 @default.
• W4362561513 cites W3041341523 @default.
• W4362561513 cites W3082426992 @default.
• W4362561513 cites W3115270138 @default.
• W4362561513 cites W3165465754 @default.
• W4362561513 cites W3165500155 @default.
• W4362561513 cites W3176093986 @default.
• W4362561513 cites W3191015088 @default.
• W4362561513 cites W3198165708 @default.
• W4362561513 cites W3205607762 @default.
• W4362561513 cites W4205166624 @default.
• W4362561513 doi "https://doi.org/10.3389/fonc.2023.1106434" @default.
• W4362561513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37081973" @default.
• W4362561513 hasPublicationYear "2023" @default.
• W4362561513 type Work @default.
• W4362561513 citedByCount "0" @default.
• W4362561513 crossrefType "journal-article" @default.
• W4362561513 hasAuthorship W4362561513A5030939408 @default.
• W4362561513 hasAuthorship W4362561513A5052637717 @default.
• W4362561513 hasAuthorship W4362561513A5074473725 @default.
• W4362561513 hasAuthorship W4362561513A5075358038 @default.
• W4362561513 hasAuthorship W4362561513A5081067710 @default.
• W4362561513 hasAuthorship W4362561513A5082909666 @default.
• W4362561513 hasAuthorship W4362561513A5087899687 @default.
• W4362561513 hasBestOaLocation W43625615131 @default.
• W4362561513 hasConcept C104317684 @default.
• W4362561513 hasConcept C121608353 @default.
• W4362561513 hasConcept C126322002 @default.
• W4362561513 hasConcept C127561419 @default.
• W4362561513 hasConcept C142724271 @default.
• W4362561513 hasConcept C147483822 @default.
• W4362561513 hasConcept C167672396 @default.
• W4362561513 hasConcept C203014093 @default.
• W4362561513 hasConcept C204232928 @default.
• W4362561513 hasConcept C2776107976 @default.
• W4362561513 hasConcept C2777701055 @default.
• W4362561513 hasConcept C2779217266 @default.
• W4362561513 hasConcept C2780851360 @default.
• W4362561513 hasConcept C2781053074 @default.
• W4362561513 hasConcept C502942594 @default.
• W4362561513 hasConcept C55493867 @default.
• W4362561513 hasConcept C71924100 @default.
• W4362561513 hasConcept C86803240 @default.
• W4362561513 hasConcept C8891405 @default.
• W4362561513 hasConceptScore W4362561513C104317684 @default.
• W4362561513 hasConceptScore W4362561513C121608353 @default.
• W4362561513 hasConceptScore W4362561513C126322002 @default.
• W4362561513 hasConceptScore W4362561513C127561419 @default.
• W4362561513 hasConceptScore W4362561513C142724271 @default.
• W4362561513 hasConceptScore W4362561513C147483822 @default.
• W4362561513 hasConceptScore W4362561513C167672396 @default.
• W4362561513 hasConceptScore W4362561513C203014093 @default.
• W4362561513 hasConceptScore W4362561513C204232928 @default.
• W4362561513 hasConceptScore W4362561513C2776107976 @default.
• W4362561513 hasConceptScore W4362561513C2777701055 @default.
• W4362561513 hasConceptScore W4362561513C2779217266 @default.
• W4362561513 hasConceptScore W4362561513C2780851360 @default.

• next